Physician profile
Mark D Emenecker
NPI 1285740571
$6,507.35
in general payments reported to CMS, 2019-2025
29 companies · $554 in 2025
The $554 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $1,056 · 2021: $878 · 2022: $1,004 · 2023: $1,083 · 2024: $685 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,321.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,047.41 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $974.65 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $658.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $645.82 | 2019-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $568.26 | 2019-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $479.52 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Novartis Pharmaceuticals Corporation | $288.60 | 2019-2024 | |
| Mylan Specialty L.P. | $203.48 | 2021-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $197.32 | 2022-2025 | |
| Organogenesis INC. | $182.38 | 2019-2020 | |
| Pfizer INC. | $182.21 | 2019-2025 | |
| Exact Sciences Corporation | $127.87 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $112.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $111.86 | 2019-2021 | |
| Esperion Therapeutics, INC. | $100.62 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $88.05 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.79 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $79.83 | 2020-2021 | |
| Daiichi Sankyo INC. | $74.46 | 2021-2024 | Injectafer |
| Abbvie INC. | $66.71 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $44.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.23 | 2019-2023 | Gattex |
| Teva Pharmaceuticals USA, INC. | $40.43 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $27.88 | 2019 | |
| Viatris Specialty LLC | $20.35 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $17.56 | 2020 | |
| Phathom Pharmaceuticals, INC. | $17.54 | 2024 | Voquezna |
| Corcept Therapeutics | $14.16 | 2019 | |
| Circassia INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Emenecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.